Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis.

Objective: The present study aims at demonstrating the equivalence of the 28-day and 3-month formulations of triptorelin SR (sustained release) in terms of percentage of patients achieving castration levels of estradiol (<==50 pg/mL) 84 days after treatment initiation.

Design: A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis.

Setting: Academic hospitals.